UBS Group’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
|
|||||
|
2025
Q1 | $29.7K | Sell |
|
|||||
|
2024
Q4 | $56.8K | Sell |
|
|||||
|
2024
Q3 | $79.9K | Buy |
|
|||||
|
2024
Q2 | $1.86K | Sell |
|
|||||
|
2024
Q1 | $7.99K | Sell |
|
|||||
|
2023
Q4 | $25.1K | Sell |
|
|||||
|
2023
Q3 | $20.8K | Sell |
|
|||||
|
2023
Q2 | $35.7K | Buy |
|
|||||
|
2023
Q1 | $17.8K | Sell |
|
|||||
|
2022
Q4 | $37.7K | Buy |
|
|||||
|
2022
Q3 | $37K | Buy |
|
|||||
|
2022
Q2 | $22K | Buy |
|
|||||
|
2022
Q1 | – | Sell |
|
|||||
|
2021
Q4 | $30K | Sell |
|
|||||
|
2021
Q3 | $48K | Buy |
|
|||||
|
2021
Q1 | – | Sell |
|
|||||
|
2020
Q4 | $26K | Buy |
|
|||||
|
2020
Q3 | $11K | Sell |
|
|||||
|
2020
Q2 | $58K | Buy |
|
|||||
|
2020
Q1 | – | Sell |
|
|||||
|
2019
Q4 | $3K | Buy |
|
|||||
|
2019
Q2 | – | Sell |
|
|||||
|
2019
Q1 | $49K | Buy |
|
|||||
|
2018
Q4 | $42K | Sell |
|
|||||
|
2018
Q3 | $56K | Sell |
|
|||||
|
2018
Q2 | $64K | Buy |
|
|||||
|
2018
Q1 | $10K | Buy |
|
|||||
|
2017
Q1 | – | Sell |
|
|||||
|
2016
Q4 | $24K | Buy |
|
|||||
|
2016
Q2 | – | Sell |
|
|||||
|
2016
Q1 | $17K | Sell |
|
|||||
|
2015
Q4 | $25K | Buy |
|